Crucell (CRXL)

[surf1944]

2:39AM Crucell N.V. announces collaboration with GlaxoSmithKline Biologicals on second generation malaria vaccine candidate (CRXL) 20.49 : Co announces that it has signed a binding letter of agreement with GlaxoSmithKline Biologicals (GSK) to collaborate on developing a second generation malaria vaccine candidate. Pre-clinical data from earlier studies indicated significantly enhanced immune responses against the malaria parasite (circumsporozoite stage of the Plasmodium falciparum) when Crucell's Adenovirus (AdVac) technology and GSK's RTS,S/AS technology are used in combination, vs either component alone. Under the terms of the letter of agreement, Crucell will contribute its recombinant malaria vaccine candidate, Ad35-CS, based on Crucell's AdVac technology and PER.C6 manufacturing platform and GSK will contribute its late stage malaria vaccine candidate RTS,S/AS. Financial details of the agreement were not disclosed.